FLIER JEFFREY S. sold $164K of SRRK

FLIER JEFFREY S. sold 3,053 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.53–$54.88, $0.16M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FLIER JEFFREY S.
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

The disclosed open-market sale by a director, executed under a pre-arranged 10b5-1 plan, is typically not a standalone fundamental driver for the stock.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

The article does not state whether the director’s remaining holdings changed meaningfully versus prior plans, nor does it provide context on total compensation or prior sale cadence.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-06 for a sale executed 2026-07-01.

Background

The article is an SEC Form 4 insider transaction disclosure for Scholar Rock Holding Corp (SRRK).

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding director Jeffrey S. Flier sold about 3,053 shares in open-market transactions under a 10b5-1 plan, totaling $164,490.

Expected impact

Limited near-term impact; any effect is likely short-lived unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through from a single director sale under 10b5-1.

None indicated.

None indicated.

Counterpoint

Insider sales can still coincide with private information, but the 10b5-1 designation materially lowers that probability.

Key entities

  • Scholar Rock Holding Corp

    Company whose director insider sale is disclosed via SEC Form 4.

  • FLIER JEFFREY S.

    Director who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 8/10

Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

Scholar Rock (SRRK) reported Q3 2026 earnings, highlighting FDA approval of ISEMBYLD for SMA, a $205M deal for a priority review voucher, and progress in Japan and Phase II FORGE study. ISEMBYLD showed a 2.2-point motor function improvement in trials, with strong early launch demand. The company reported $0.6M in ISEMBYLD revenue and $413.6M in cash, with no immediate need for equity offering.

$SRRKLow

What Scholar Rock (SRRK) Said on Its Q3 Earnings Call

Scholar Rock (SRRK) reported Q3 earnings, noting no demand impact from a bone fracture warning. The company resubmitted its European marketing application for apitegromab, expecting a decision in early 2027. It anticipates a 2027 launch in Japan and Germany. Operating expenses were $106.6M, with $413.6M in cash. SRRK sold a priority review voucher for $205M and has access to an additional $150M under its debt facility.

$SRRKHighAI 8/10

Raymond James reiterates Strong Buy on Scholar Rock stock after Q3 results

Raymond James maintained a Strong Buy rating and $72.00 price target for Scholar Rock (NASDAQ: SRRK) after its Q3 2026 results. The stock is up 17% this week and 76% over the past year. Scholar Rock reported its first product revenues for ISEMBYLD, which received FDA approval in September 2026. The company's EPS beat estimates but revenue missed expectations, falling 60.14% short of forecasts.